Special Issue

Novel Targets for the Pathogenesis of Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is a lethal malignancy with limited therapeutic options for long-term survival. It is the fourth leading cause of cancer-related death and represents 7% of all cancers. Pancreatic cancer develops through non-invasive epithelial proliferation of pancreatic ducts and mutation of driver genes KRAS, CDKN2A, TP53, and SMAD4. Surgical resection and adjuvant chemotherapy with gemcitabine are only an option in the later stages of the disease. Combination therapy or polytherapy, which uses two or more therapeutic agents to treat cancer patients, is more popular. This type of therapy targets key pathways in a synergistic or additive manner compared to the monotherapy approach. It is, however, important to use FDA-approved repurposed pharmaceutical agents in this combination therapy, which may be beneficial for patients in terms of financial burden. This Special Issue focuses on exploring the therapeutic and potential targets in pancreatic cancer. We invite articles related to all aspects of pancreatic cancer pathogenesis and treatment. There are no specifications or limitations on the type of studies used in pancreatic cancer.

Guest Editor

Dr. Palanisamy Nallasamy

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

closed (31 December 2022)



Medicines

an Open Access Journal by MDPI

Indexed in PubMed



mdpi.com/si/70368

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

mdpi.com/journal/ medicines





Medicines

an Open Access Journal by MDPI

Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Medicines (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).

